Regenerative medical devices company. Tissue Regenix Group (TRX) , announced on Thursday the launch of a product line extension, 'DermaPure Non- Oriented', an expansion of its flagship dCELL® Technology product, DermaPure.
DermaPure Non-Oriented, a product specifically tailored for the surgical and trauma markets, was unveiled at the American Urogynecologic Society, an annual meeting in Nashville last week, the company revealed.
The product, which is now available for distribution, is processed using dCELL® Technology and has two identical sides -- meaning the orientation of the graft is not a factor therefore enhancing the ease of application.
The primary indication for this product line will be uro-gynecological procedures, where Tissue Regenix have already established a strong working relationship with partner and specialist distributor, ARMS Medical.
Interim Chief Executive of Tissue Regenix Group, Gareth Jones, commented:
"Our commercial success is predicated on our ability to identify new clinical applications and rapidly develop product lines to meet this demand.
Working closely with our strategic partner, ARMS Medical, we are confident that DermaPure Non-Oriented will offer our clinicians the clinical outcomes and health economic benefits they require.
We continue to see the growing demand for DermaPure, as demonstrated in our recent interim results, and expect that DermaPure Non-Oriented will augment this product portfolio, driving adoption by physicians in the future."
Follow News & Updates from Tissue Regenix Group here: